公开(公告)号：EP0666253A1

公开(公告)日：1995-08-09

申请号：EP93923036.3

申请日：1993-10-20

申请人： TAISHO PHARMACEUTICAL CO. LTD ,  MITSUI PETROCHEMICAL INDUSTRIES, LTD.

发明人： MIYOSHI, Toshio, Taisho Pharmaceutical Co., Ltd. ,  ASAMI, Yumiko, Taisho Pharmaceutical Co., Ltd. ,  SATO, Masakazu, Taisho Pharmaceutical Co., Ltd. ,  ISHIGURO, Masaharu, Mitsui Petrochemical Ind., Ltd ,  KITAHARA, Takumi, Mitsui Petrochemical Ind., Ltd. ,  TOMINO, Ikuo, Mitsui Petrochemical Ind., Ltd.

IPC分类号： C07C317/36 ,  C07C317/40 ,  C07C323/37 ,  C07C323/41 ,  A61K31/135 ,  A61K31/14 ,  A61K31/16

CPC分类号： C07C323/37 ,  C07C317/36 ,  C07C323/41

摘要： An N-t-butylaniline analog represented by general formula (I) or a salt thereof, and a lipid level depressant containing the same as the active ingredient. In said formula, R¹ and R², which may be the same or different from each other, represent each hydrogen, halogen, amino, nitro, acetamide, lower alkyl, lower alkoxy, halogenated lower alkyl, halogenated lower alkoxy or lower alkanoyl; R³ represents hydrogen, halogen, lower alkoxy or halogenated lower alkyl; and Z represents S, SO or SO₂. This compound has a remarkably excellent effect of depressing the lipid level as compared with clofibrate and 4-(N-t-butyl)methanesulfonylaminodiphenyl ether and is extremely reduced in toxicity.

摘要翻译： 由通式（I）表示的N-叔丁基苯胺类似物或其盐，以及含有与活性成分相同的脂质降低剂。 在所述式中，R 1和R 2可以彼此相同或不同，表示氢，卤素，氨基，硝基，乙酰胺，低级烷基，低级烷氧基，卤代低级烷基，卤代低级烷氧基 或低级烷酰基; R 3表示氢，卤素，低级烷氧基或卤代低级烷基; Z表示S，SO或SO 2。 与氯贝特和4-（N-叔丁基）甲磺酰氨基二苯醚相比，该化合物具有显着优异的抑制脂质水平的作用，毒性极度降低。

公开(公告)号：EP0930314A1

公开(公告)日：1999-07-21

申请号：EP97933907.4

申请日：1997-08-05

申请人： TAISHO PHARMACEUTICAL CO. LTD

发明人： HATAYAMA, Katsuo ,  SATO, Masakazu, Taisho Pharmaceutical Co., Ltd. ,  MANAKA, Akira, Taisho Pharmaceutical Co., Ltd. ,  TAKAHASHI, Keiko, Taisho Pharmaceutical Co., Ltd. ,  KAWASHIMA, Yutaka, Taisho Pharmaceutical Co., Ltd. ,  HATAYAMA, Sachiko

IPC分类号： C07D491/113 ,  A61K31/445

CPC分类号： C07D491/10

摘要： p-Toluenesulfonate dihydrate of a thiazoline compound represented by the formula: and a fibrinogen receptor antagonist comprising the same as an effective component.
The present invention provides a compound which has an excellent fibrinogen receptor antagonism, and is easy to store and to produce the pharmaceutical preparation for oral administration because of the compound's non-hygroscopic property.

摘要翻译： 由下式表示的噻唑啉化合物的对甲苯磺酸盐二水合物：＆lt; IMAGE＆gt;和包含与有效成分相同的纤维蛋白原受体拮抗剂。 本发明提供了具有优异纤维蛋白原受体拮抗作用的化合物，由于该化合物的非吸湿性，易于储存和制备用于口服给药的药物制剂。

公开(公告)号：EP1609799A1

公开(公告)日：2005-12-28

申请号：EP04708901.6

申请日：2004-02-06

申请人： TAISHO PHARMACEUTICAL CO., LTD

发明人： KAKINUMA, Hiroyuki, Taisho Pharmaceutical Co., Ltd ,  SATO, Masakazu, Taisho Pharmaceutical Co., Ltd. ,  AMADA, Hideaki, Taisho Pharmaceutical Co., Ltd. ,  ASANUMA, Hajime, Taisho Pharmaceutical Co., Ltd. ,  TSUCHIYA, Yuko, Taisho Pharmaceutical Co., Ltd.

IPC分类号： C07H17/02 ,  A61K31/7056 ,  A61P3/10 ,  A61P43/00

CPC分类号： A61K31/706 ,  A61K31/7056 ,  C07H17/00 ,  C07H17/02

摘要： There is provided a heteroaryl 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.

摘要翻译： 提供了对SGLT2活性具有抑制作用的下式的杂芳基5-硫代-β-D-吡喃葡萄糖苷化合物或其药学上可接受的盐或其水合物。 还提供了药物制剂，特别是糖尿病，糖尿病相关疾病或糖尿病并发症的预防或治疗剂，其包含这种化合物作为活性成分。